胞磷胆碱治疗卒中后认知障碍患者的临床研究  

Clinical trial of citicoline in the treatment of patients with post-stroke cognitive impairment

作　　者：高昶[1,2] 刘燕 聂琼 王新宇 张翠翠 GAO Chang;LIU Yan;NIE Qiong;WANG Xin-yu;ZHANG Cui-cui(School of Mental Health,Jining Medical University,Jining 272067,Shandong Province,China;Graduate Office,Jining Medical University,Jining 272067,Shandong Province,China;Clinical Medical School,Jining Medical University,Jining 272067,Shandong Province,China;ThirdDepartment of Critical Care Medicine,Affliated Hospital of Jining MedicalUniversity,Jining 272029,Shandong Province,China)

机构地区：[1]济宁医学院精神卫生学院,山东济宁272067 [2]济宁医学院研究生处,山东济宁272067 [3]济宁医学院临床医学院,山东济宁272067 [4]济宁医学院附属医院重症医学三科,山东济宁272029

出　　处：《中国临床药理学杂志》2024年第19期2801-2805,共5页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金项目资助项目(81901391);山东省政府泰山学者青年专家人才计划基金资助项目(tsqn201909145);山东省济宁市重点研发计划基金资助项目(2019SMNS001);济宁医学院贺林基金资助项目(JYHL2021 MS04)。

摘　　要：目的观察胞磷胆碱钠片联合石杉碱甲片治疗卒中后认知障碍患者的临床疗效及安全性。方法将卒中后认知障碍患者按队列法分为对照组和试验组。对照组口服石杉碱甲片,每次0.1~0.2 mg,bid;试验组在对照组治疗的基础上,口服胞磷胆碱钠片,每次0.2 g,tid。2组患者均治疗12周。比较2组患者的临床疗效、认知功能[简易智力状态检查量表(MMSE)评分、美国国立卫生研究院卒中量表评分、Barthel指数]、神经功能、日常生活能力以及血清血管内皮生长因子(VEGF)、脑源性神经营养因子(BDNF)水平,并评价安全性。结果试验组和对照组各入组100例。治疗后,试验组和对照组的总有效率分别为92.00%(92例/100例)和75.00%(75例/100例),在统计学上差异有统计学意义(P<0.05)。治疗后,试验组和对照组的MMSE评分分别为(23.40±2.43)和(19.35±2.51)分,美国国立卫生研究院卒中量表评分分别为(12.25±1.24)和(15.84±1.61)分,Barthel指数分别为(71.14±8.60)和(64.26±8.33)分,VEGF水平分别为(191.52±14.80)和(125.73±11.48)pg·mL^(-1),BDNF水平分别为(9.47±1.59)和(8.01±1.35)ng·mL^(-1),试验组的上述指标与对照组比较,在统计学上差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有头晕、恶心,对照组的药物不良反应主要有头晕、恶心。试验组和对照组的总药物不良反应发生率分别为8.00%(8例/100例)和5.00%(5例/100例),在统计学上差异无统计学意义(P>0.05)。结论胞磷胆碱钠片联合石杉碱甲片治疗卒中后认知障碍患者的疗效确切,对患者认知功能、神经功能具有明显的改善作用,安全性良好。Objective To observe the clinical efficacy of citicoline sodium tablets combined with huperzine A tablets in the treatment of patients with cognitive impairment after stroke,and to explore the influence on neurological function and serum levels of vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF).Methods Patients with cognitive impairment after stroke were classified into control group and treatment group according to cohort method.The control group was given oral administration of huperzine A tablets 0.1-0.2 mg for twice a day,while the treatment group was given0.2 g citicoline sodium tablets orally for three times a day on the basis of the control group.Both groups of patients were treated for 12 weeks.The clinical efficacy,cognitive function[Mini-Mental State Examination(MMSE),National Institute of Health stroke scale,Barthel index],neurological function and daily living ability and serum vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF)levels were compared and safety was evaluated.Results One hundred patients were enrolled in the experimental group and the control group.After treatment,the total effective rates in treatment gr oup and control group were 92.00%(92 cases/100 cases)and 75.00%(75 cases/100 cases)with significant difference(P<0.05).The MMSE scores in treatment group and control group after treatment were(23.40±2.43)and(19.35±2.51)points;the scores of National Institutes of Health Stroke Scale were(12.25±1.24)and(15.84±1.61)points;the Barthel Index scores were(71.14±8.60)and(64.26±8.33)points;VEGF levels were(191.52±14.80)and(125.73±11.48)pg·mL^(-1);BDNF levels were(9.47±1.59)and(8.01±1.35)ng·mL^(-1).There were statistically significant differences in the above indexes between the treatment group and the control group(all P<0.05).The adverse drug reactions in the treatment group were mainly dizziness and nausea,and the adverse drug reactions in the control group were mainly dizziness and nausea.The incidence rates of ad

关 键 词：胞磷胆碱钠片 石杉碱甲片 卒中后认知障碍 神经功能 血管内皮生长因子 脑源性神经营养因子 安全性评价 

分 类 号：R971[医药卫生—药品]